Introduction
During the last years, enormous progress has been made in the ex vivo manufacturing of human red blood cells (RBCs). Using human hematopoietic stem cells (HSCs) from cord blood (CB) or bone marrow (BM) as the primary source, expansion rates higher than 10 5 -fold [1] [2] [3] [4] [5] [6] , accompanied by fully terminal maturation into enucleated reticulocytes [1] [2] [3] [4] , were achieved. Recently, the first proof-of-principle experiment was performed by transfusing a small sample of manufactured RBCs into a human recipient. 7 However, despite this achievement, the large-scale expansion of RBCs for transfusion purposes (1 RBC unit contains 10 12 RBCs) remains poorly accessible, as human HSCs are a limited source. Up to now, protocols for the ex vivo expansion of multipotent HSCs are not available.
One promising alternative might be the generation of RBCs from human pluripotent stem cells, a theoretically unlimited source characterized by its self-renewing properties. Until recently, the ex vivo generation of RBCs from human embryonic stem cells (hESCs) was limited due to ethical concerns. Furthermore, it is unknown, if any of the hESC lines approved in the USA and produced under good manufacturing practice conditions, has the universal 0 rhesus negative phenotype. 8 These limitations were overcome by the discovery of induced pluripotent stem cells (iPSCs). Human iPSCs, which resemble hESCs in vitro and in vivo, were initially generated from fibroblasts through the ectopic expression of a combination of the transcription factors OCT4, SOX2, KLF4, c-MYC as well as NANOG and LIN28. [9] [10] [11] Since these first reports, iPSCs have been derived from various tissues. [12] [13] [14] [15] [16] Our group reported the generation of iPSCs from human neural stem cells (NSCs) by reprogramming with only OCT4 due to their endogenous expression of pluripotencyassociated genes. 15 More recently, first protocols were established to induce RBC development from human fibroblast-derived iPSCs. [17] [18] [19] [20] [21] [22] However, in vitro recapitulation of physiological erythropoiesis in its entirety, which includes mesoderm induction, generation of HSCs, erythroid maturation, hemoglobin switching and enucleation, remains a challenge. Compared to the established protocols for the adult system, RBC generation from iPSCs is less efficient. In addition to a poor expansion rate of erythroid cells, ex vivo-generated cells from iPSCs fail in terminal differentiation, particularly enucleation and switching from embryonic to fetal and finally adult hemoglobin.
Increasing evidence from murine 23, 24 and human systems 25, 26 indicates that iPSCs exhibit an epigenetic memory related to their donor cell type of origin. Although iPSCs exhibit characteristics and behaviors of ESCs, incomplete removal of tissue-specific methylation or aberrant de novo methylation has been observed, which might influence their differentiation behavior. Due to the potential epigenetic memory and its influence on hematopoietic differentiation, iPSCs from CD34+ HSCs may be more suitable for erythroid differentiation than commonly used fibroblast-derived iPSCs.
To investigate the influence of an epigenetic memory on the ex vivo expansion of iPSCs into hematopoietic and erythroid cells, we generated iPSC lines from human CB-derived CD34+
HSCs and human NSCs. 15 We evaluated their global gene methylation status and their potential to differentiate into hematopoietic progenitors and mature RBCs under ex vivo conditions. Whereas CD34+ HSCs are the physiological source for RBCs in humans and are of mesodermal origin, NSCs are derived from the ectodermal germ layer. For the sake of completeness, fibroblast-derived iPSCs 27 and hESCs H1 have been included in our study as "controls".
Methods

Generation of human CB CD34+ iPSCs
CD34+ HSCs were isolated from human CB, using MACS sorting (Miltenyi Biotec, Germany).
Informed consent was obtained from the donating mothers, and the investigation was approved by the Ethics Committee of Heinrich-Heine-University Düsseldorf Medical School.
CD34+ cells were stimulated with SCF, TPO, FLT3-L and IL-6 as described 28 Approximately 25 days after transduction, iPSC colonies were selected for further expansion on the basis of their morphology. Established CD34+ iPSC lines were characterized as described. 32 The generation and characterization of iPSCs from human NSCs with OCT4
and KLF4 (NSC-2F-iPSCs) or only OCT4 (NSC-1F-iPSCs) by our group was previously described. 15 Likewise, the generation of iPSCs from human skin fibroblasts (Fib-iPSCs) with OCT4, SOX2, KLF4 and c-MYC has been described. 27 H1-hESCs were obtained from WiCell (WI, USA).
Global gene expression analysis
RNA samples for microarray analysis were prepared using RNeasy columns (Qiagen, Germany). 300ng of total RNA per sample was used as the input in the linear amplification protocol (Ambion), with 12hrs of in vitro transcription incorporating the biotin-labeled nucleotides. Purified and labeled cRNA was hybridized onto HumanHT-12 v4 expression BeadChips (Illumina, USA) following the manufacturer's instructions. The chips were stained with streptavidin-Cy3 (GE Healthcare) and scanned using the iScan reader (Illumina).
Methods for the microarray data processing are available online (Supplements).
Global DNA methylation analysis
Genomic DNA was extracted from human iPSCs (passages >15) and the corresponding somatic cell populations. The methylation status of all promoter associated CpG islands was analyzed. Detailed methods are available online (Supplements).
Hematopoietic and erythroid differentiation
Human ESCs H1 (n=6) and iPSCs (n=4 respectively n=3 for NSC-2F-iPSCs, passages >15)
were differentiated into hematopoietic cells using the embryoid body (EB) method, as previously described 18 ( Figure 1 , Table 1 ). EBs were stimulated for 20 days with 100ng/mL SCF, 100ng/mL TPO, 100ng/mL Flt3-L, 5ng/mL IL-3, 5ng/mL IL-6, 5ng/mL vascular endothelial growth factor 165, BMP4 (20ng/mL until day 9, then 10ng/mL) (all from Peprotech, USA) and 3U/mL erythropoietin (EPO, Erypo ® , Janssen-Cilag, Germany). Day 21
EBs were dissociated into single cells using collagenase B (0.4U/mL; Roche Diagnostics, Germany). 33 For erythroid differentiation, single cells were cultured for up to 25 days in Iscove's liquid medium (Biochrom, Germany) containing 10% human plasma (Octapharm, Germany), 10μg/mL insulin (Sigma Aldrich, Germany) and 330μg/mL human holo transferrin (Spicac, UK). Cells were stimulated with the following cytokines: day 0 to day 8: 100ng/mL SCF, 5ng/mL IL-3 and 3U/mL EPO; day 8 to day 11: 100ng/mL SCF and 3U/mL EPO; day 11 to day 25: 3U/mL EPO.
Hematopoietic and erythroid development was monitored by flow cytometry, colony formation in semisolid media and microscopic evaluation of cell morphology. The hemoglobin composition was analyzed by high performance liquid chromatography and PCR analysis.
Detailed methods are available online (Supplements).
Results
Induction of pluripotency in human CB CD34+ HSCs
CD34+ HSCs from human CB were reprogrammed to pluripotency using lentiviral vectors expressing either OCT4 and SOX2 alone (CD34-2F-iPSCs) or expressing OCT4, SOX2, KLF4 and c-MYC (CD34-4F-iPSCs) as a polycistronic unit under the control of the retroviral SFFV promoter. 29, 30 The transduction efficiency of the CD34+ HSCs was approximately 70%
and yielded different quantities of ESC-like colonies, which were further propagated (Suppl. Figure 1A ). Immunofluorescence staining was performed to detect the expression of the pluripotency markers OCT4, NANOG, SSEA4, Tra1-60 and Tra1-81 (Suppl. Figure 1C and 1D) as well as alkaline phosphatase staining (Suppl. Figure 1B) . Silencing of the SFFV promoter after reprogramming was demonstrated by the absence of red fluorescent protein expression in the iPSC colonies. This was further validated using qRT-PCR with vectorspecific primers (Suppl. Figure 1F ). To evaluate the in vivo pluripotency, CD34+ iPSCs were subcutaneously transplanted into severe combined immunodeficient mice. Approximately eight weeks after injection, the CD34+ iPSCs gave rise to teratomas containing derivatives of all three germ layers, including neural rosettes (ectoderm), smooth muscle and chondrocytic elements (mesoderm) and gut-like structures (endoderm) (Suppl. Figure 1E ).
Global gene expression profiling of human CB CD34+ iPSCs
To demonstrate successful reprogramming to pluripotency, global gene expression of CD34+
iPSCs was compared to the expression profile of hESCs and the parental CD34+ population.
The canonical pluripotency factors POU5F1/OCT4, SOX2, LIN28, KLF4 and cMYC line up on the diagonal in the pairwise scatter blot comparing the CD34+ iPSCs and H1-hESCs ( Figure 2A ). 98.1% of the transcripts were similarly expressed (using a two-fold threshold in log2 scale) in the CD34+ iPSCs and H1-hESCs. The distance between the populations was reduced to 0.019, becoming more than 3-fold closer in distance, relative to the parental CD34+ population, which demonstrates successful reprogramming to pluripotency.
Hierarchical clustering analysis showed that CD34+ iPSCs clustered closely with hESCs (H1 and H9) and were distinct from parental CB CD34+ HSCs ( Figure and RUNX1 (Suppl. Figure 6 ). As a general trend, we could not detect higher methylation levels for the NSC iPSCs compared with the CD34+ iPSCs at the analyzed hematopoietic loci. At the EPO and GATA2 loci the methylation levels are lower in the case of the CD34+ iPSCs than in the NSC iPSCs (red versus blue bars in Suppl. Figure 3 ).
Hematopoietic differentiation of human CB CD34+ and NSC iPSCs
Hematopoietic differentiation of iPSCs (n=4 respectively n=3 for NSC-2F-iPSCs, passages iPSCs. CD34-2F-iPSCs gave rise to a lower total number of colonies ( Figure 3C and 3D).
Erythroid differentiation of human CB CD34+ and NSC iPSCs
To and keratinocyte-derived iPSCs. [23] [24] [25] [26] This differentiation impairment was pronounced in earlypassage iPSC lines (<p10) and was attenuated at later passages (>p15). 25 Due to the potential epigenetic memory and its influence on hematopoietic differentiation pathways, CD34+ HSCs may be a more suitable as a reprogramming starting population to induce RBC generation from human iPSCs than commonly used fibroblasts.
To examine this issue further, we compared the hematopoietic and erythroid development of two new established CD34+ iPSC lines with NSC-derived iPSCs, which were recently described by our group. 15 Both populations are of fetal origin and can be classified as multipotent, somatic stem cells. Whereas CD34+ HSCs are the physiological progenitors of RBCs and are of mesodermal origin, NSCs are derived from the ectodermal germ layer. To make our results more comparable with those of other publications, we also included fibroblast-derived iPSCs in our study. 27 Previously we demonstrated that multipotent NSCs are more amenable to reprogramming to iPSCs than unipotent fibroblasts. 37 This observation was further validated with hematopoietic 38 and endodermal 39 cells.
To analyze the epigenetic marks of the reprogrammed cells, we performed genome-wide DNA methylation analysis of various iPSC lines (all at passages >15) derived from different sources (CD34+ HSCs, NSCs, MSCs and USSCs) being aware that DNA methylation is just one parameter leading to variations among iPSC lines. 40 Our results indicate that all iPSCs have an epigenetic memory as shown by their global methylation profile at promoter regions.
This was confirmed by hierarchical clustering and principal component analyses, demonstrating that all iPSCs cluster together with their corresponding somatic stem cells.
For hematopoietic and erythroid differentiation, human CD34+ HSC-, NSC-and fibroblastderived iPSCs (passages >15) were applied to an EB-based culture system described recently. 18 Despite the observed epigenetic memory in global gene methylation, all iPSC lines performed similarly in the initial hematopoietic induction, independent of their somatic origin. The hematopoietic commitment, analyzed by CD43 expression after 21 days of cytokine stimulated EB formation, averaged 20%, with some passage-dependent variations in each cell line. This is consistent with Bock et al. 41 , who postulated, based on quantitative EB differentiation assays, differentiation variations among iPSC lines within the normal spectrum of ESC variation. CD43 was recently identified as a hematopoiesis specific marker that is expressed in early hematopoietic progenitors and persists in differentiating precursor cells. 42 In line with others, we observed only a minor population of CD45+/CD34+ or CD43+/CD34+ hematopoietic progenitors (~2%). [17] [18] [19] [20] [21] [22] 43 The vast majority of the CD43 hematopoietic cells were already committed myeloid, megakaryocyte and erythroid precursors. Additionally, the colony-forming potential of the digested day 21 EB cells showed no obvious differences between the CD34+ iPSCs, NSC iPSCs and Fib iPSCs; only the frequency of erythroid colonies was slightly higher in the CD34-4F-iPSCs. 1.96x10 6 fold will theoretically allow for the generation of more than 3x10 12 RBCs from one CB unit. 1 However, the erythroid differentiation potential of the human iPSCs described here is similar to recent reports using fibroblast and MSC-derived iPSCs in EB 18, 21 or stromal layer-based culture systems. 17, 20 Although using different culture conditions, all studies describe a severely limited expansion of the erythroid cells compared to adult HSCs, a low enucleation rate (<10%) and the expression of mainly fetal and embryonic hemoglobin.
Compared to these results, we achieved a higher enucleation rate (21-29% vs. <10% [17] [18] [19] [20] [21] [22] ), which might be caused by differences in the culture techniques or by intrinsic characteristics of our iPSC cell lines.
Because of the similar functionality of NSC and CB CD34+-derived iPSCs in hematopoietic and erythroid differentiation, we focused the initial DNA methylation analysis in more detail on promoter regions associated with hematopoietic and erythroid differentiation pathways.
We did not detect higher methylation levels at many of the hematopoietic-specific promoters in the NSC iPSCs compared to the CD34+ iPSCs. A higher methylation level in NSC iPSCs, indicating the impaired transcription of these regions, could be considered a prerequisite for the preferred differentiation of CD34+ iPSCs towards hematopoietic lineages. Therefore, these results support the observed similarity in hematopoietic and erythroid differentiation between the NSC iPSCs and CD34+ iPSCs. In addition to our results, it would be of high interest to further investigate reprogrammed erythroid progenitors regarding their hematopoietic potential and epigenetic marks. The succesful reprogramming of erythroid progenitors derived from patients with polycythemia vera has been described recently.
44
One recent study observed that our iPSCs derived from mouse NSCs with OCT4 alone showed reduced neuronal and hematoendothelial differentiation compared to iPSCs reprogrammed with all four factors or ESCs. 45 This might be the result of some epigenetic instability, as shown in the DNA methylation pattern of the pluripotency associated promoters, although their gene expression profile was highly similar to that of ESCs. 46 We can confirm these slight differences in the differentiation efficiency in human cells depending on the number of reprogramming factors. Although OCT4-derived (NSCs) and OCT4/SOX2-derived (CD34+ HSCs) iPSCs gave rise to similar percentages of hematopoietic precursors compared to their corresponding iPSC lines that were reprogrammed with more factors, colony growth was impaired in CD34+ iPSCs reprogrammed with only OCT4/SOX2.
Furthermore, the outcome of the erythroid cells in the more specific erythropoiesis assays was likewise impaired in OCT4-induced NSC iPSCs and OCT4/SOX2-induced CD34+
iPSCs. Nevertheless, all iPSC lines gave rise to erythroid cells at terminally mature stages, and the expansion rates were at least as high as in H1-hESCs.
Although we can confirm our initial hypothesis of an epigenetic memory in CD34+ iPSCs at higher passages on a genome-wide level, this memory only marginally improved the expansion and differentiation of RBCs under ex vivo conditions. Therefore, RBC generation from iPSCs still remains a challenge, and major hurdles must be overcome before iPSCderived RBCs will have entrance into clinical use. One key-issue for transfusion purposes will be the large-scale amplification. Strategies to improve expansion rates might focus on increased induction of early hematopoietic and erythroid progenitors from human iPSCs and the maximization of their subsequent expansion (e.g. by controlled expression of erythroid specific genes, introduction of proliferation-associated transcription factors 47, 48 , modification of growth factor combinations or mimicry of endogeneous niches). After successful overcoming all these difficulties, ex vivo manufactured RBCs from human iPSCs might be used for personalized transfusion medicine, preferentially applied to allo-immunized patients or those with rare blood groups. For these purposes, using CB CD34+ HSCs as the starting cell population, as described here, will have several potential advantages: 1) CB CD34+ cells are of fetal origin and have not been challenged by environmental influences that lead to nuclear and mitochondrial mutations. 49, 50 2) CD34+ HSCs can be easily isolated from CB collected in an already established worldwide network of CB banks, without any donor risk. 50 3) CB derived from CB banks will be well characterized for immunological and infectious markers. 4) CB derived iPSCs would allow the formation of CB iPSC banks to procure blood group-compatible RBC units and, on demand, histocompatible cell transplants. Furthermore, in newborns with congenital diseases, autologous CB might be readily available for the generation of autologous cell products, disease modeling or genetic modifications.
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Dorn et al. Supplementary Data
These supplementary data are comprised of a supplementary methods section with references and six supplementary figures with legends.
Supplementary Methods
Characterization of human CB CD34+ iPSCs
Immunofluorescence staining of iPSC colonies was performed using the following primary 
Microarray data processing
The bead intensities were mapped to the gene information using BeadStudio 3.2 (Illumina).
Background correction was performed using the Affymetrix Robust Multi-array Analysis (RMA) background correction model. 1 Variance stabilization was performed using log2 scaling, and the gene expression data were normalized using the method implemented in the Lumi package of R-Bioconductor. Data post-processing and graphing were performed with in-house developed functions in Matlab. Hierarchical clustering of genes and samples was performed with the one minus correlation metric and the unweighted average distance (UPGMA) (also known as group average) linkage method previously described.
Global DNA methylation analysis
Genomic DNA was extracted from human iPSCs (passages >15) using the QIAamp ® DNA Blood Mini Kit (Qiagen), and 1µg of genomic DNA was sonicated to fragment sizes of 300-1000bp using a Vibra Cell 75022 Ultrasonic Processor. These DNA samples were then immunoprecipitated with an antibody against methylated DNA using the Diagenode´s MeDIP kit. Amplification of the input and output samples was performed using the Genome Plex 
Methylation data processing
The methylation state was normalyzed across samples using the quantile method. Data postprocessing and graphics was performed with in-house developed functions in Matlab.
Hierarchical clustering of genes and samples was performed with one minus correlation metric and the unweighted average distance (UPGMA) (also known as group average) linkage method. The molecular signatures were taken from the gene set collection C2 of the version 3.0 of the Molecular Signatures Database (MSigDB). 3 The significance of the gene set of the different expressed genes was analyzed using an enrichment approach based on the hypergeometric distribution. The significance (p-value) of the gene set enrichment was calculated using the hypergeometric distribution. The multitest effect influence was corrected trough controlling the false discovery rate using the Benjamini-Hochberg correction at a significance level α=0.05. For the bars plot analysis at individual loci the scaled log2 ratios of the data were used. Each feature on the array has a corresponding scaled log2 ratio, which is the ratio of the input signals for the experimental (IP) and control (input) samples cohybridized to the array. The log2 ratio is computed and scaled to center the ratio data around zero. The centering is performed by subtracting the bi-weight mean for the log2 ratio values for all features on the array from each log2 ratio value.
Monitoring hematopoietic and erythroid development
Flow cytometry: 
Hemoglobin analysis
The percentages of tetrameric hemoglobin fractions were measured by cation exchange high performance liquid chromatography (CE-HPLC) (VWR EZ Chrom Elite, Software 3.2.1) using a Bio-Rad Variant II Hb analyzer and the ß-Thalassemia kit (Bio-Rad Laboratories, CA, USA). Additionally, total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Complementary DNA synthesis was performed using M-MLV reverse transcriptase (Affymetrix) and a customized 15-bp oligo dT primer.
Semiquantitative gene specific PCR for embryonic ε-chains, fetal γ-chains and adult ß-chains was performed as previously described. 
